Patient and Healthcare Professional Preferences for Characteristics of Long-Acting Injectable Antipsychotic Agents for the Treatment of Schizophrenia.
Antipsychotic agent
Ease of use
Long-acting injectable
Schizophrenia
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
received:
14
11
2022
accepted:
08
02
2023
medline:
17
5
2023
pubmed:
12
3
2023
entrez:
11
3
2023
Statut:
ppublish
Résumé
Studies evaluating patient and healthcare professional (HCP) preferences regarding long-acting injectable (LAI) antipsychotic agent attributes are lacking. Surveys were administered to physicians, nurses, and patients who had at least two experiences with TV-46000, an investigational subcutaneous LAI antipsychotic agent for the treatment of schizophrenia, as part of the SHINE study (NCT03893825). Survey topics included preferences for route of administration, potential LAI dosing intervals (once-weekly, twice a month, once a month [q1m], every 2 months [q2m]), injection location, ease of use, syringe type, needle length, and need for reconstitution. Patients (n = 63) had a mean (SD) age of 35.6 (9.6) years, age at diagnosis of 18 (10) years, and were mostly male (75%). There were 49 HCPs: 24 physicians and 25 nurses. Patients rated "a short needle" (68%), a "choice of [q1m or q2m] dosing interval" (59%), and "injection instead of oral tablet" (59%) as the most important features. HCPs rated "single injection to initiate treatment" (61%), "flexible dosing interval" (84%), and "injection instead of oral tablet" (59%) as the most important features. Subcutaneous injections were rated "easy to [receive/administer]" by 62% of patients and 84% of HCPs. When choosing between subcutaneous injections and intramuscular injections, 65% of HCPs preferred subcutaneous injections and 57% of patients preferred intramuscular injections. It was important to most HCPs to have four dose strength options (78%), a prefilled syringe (96%), and no need for reconstitution (90%). Patients had a range of responses, and on some issues patient and HCP preferences differed. Altogether, this suggests the importance of providing patients with a range of options and the importance of patient-HCP discussions on treatment preference for LAIs. Several medications for treating schizophrenia are available as long-acting injections. One advantage of these medications is that patients do not need to take pills daily. In this study, patients, doctors, and nurses were asked what medication characteristics they preferred. Question topics were similar to the following: “how often should it be taken?”; “what method of delivery do you prefer?”; “where on the body should it be injected?”; “how easy was it to use?”; “what physical properties do you like?”; and “do preparation steps matter?” Patients thought that being able to be given monthly or every other month was one of the most important features of an injection (59%). Patients also liked a short needle (68%) and an injection instead of an oral pill (59%). Doctors and nurses responded that it was important to have a single injection to start treatment (61%). They also liked having options for how often the medication was given (84%), and an injection instead of an oral pill (59%). An injection was “easy to [get/give]” for most patients (62%) and doctors and nurses (84%). Most doctors and nurses (65%) liked giving injections under the skin. Most patients (57%) liked injections into the muscle. Overall, patients and doctors/nurses agreed on most topics. There were, however, a range of patient responses; therefore, it is important for patients and doctors and nurses to talk about the available treatment options. Each individual patient may have their own preferences.
Autres résumés
Type: plain-language-summary
(eng)
Several medications for treating schizophrenia are available as long-acting injections. One advantage of these medications is that patients do not need to take pills daily. In this study, patients, doctors, and nurses were asked what medication characteristics they preferred. Question topics were similar to the following: “how often should it be taken?”; “what method of delivery do you prefer?”; “where on the body should it be injected?”; “how easy was it to use?”; “what physical properties do you like?”; and “do preparation steps matter?” Patients thought that being able to be given monthly or every other month was one of the most important features of an injection (59%). Patients also liked a short needle (68%) and an injection instead of an oral pill (59%). Doctors and nurses responded that it was important to have a single injection to start treatment (61%). They also liked having options for how often the medication was given (84%), and an injection instead of an oral pill (59%). An injection was “easy to [get/give]” for most patients (62%) and doctors and nurses (84%). Most doctors and nurses (65%) liked giving injections under the skin. Most patients (57%) liked injections into the muscle. Overall, patients and doctors/nurses agreed on most topics. There were, however, a range of patient responses; therefore, it is important for patients and doctors and nurses to talk about the available treatment options. Each individual patient may have their own preferences.
Identifiants
pubmed: 36905498
doi: 10.1007/s12325-023-02455-8
pii: 10.1007/s12325-023-02455-8
pmc: PMC10129959
doi:
Substances chimiques
Antipsychotic Agents
0
Delayed-Action Preparations
0
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
2249-2264Informations de copyright
© 2023. The Author(s).
Références
Correll CU, Rubio JM, Kane JM. What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? World Psychiatry. 2018;17(2):149–60. https://doi.org/10.1002/wps.20516 .
doi: 10.1002/wps.20516
pubmed: 29856543
pmcid: 5980517
Pennington M, McCrone P. The cost of relapse in schizophrenia. Pharmacoeconomics. 2017;35(9):921–36. https://doi.org/10.1007/s40273-017-0515-3 .
doi: 10.1007/s40273-017-0515-3
pubmed: 28534254
Takeuchi H, Siu C, Remington G, et al. Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia. Neuropsychopharmacology. 2019;44(6):1036–42. https://doi.org/10.1038/s41386-018-0278-3 .
Yu Y, Liu ZW, Tang BW, Zhao M, Liu XG, Xiao SY. Reported family burden of schizophrenia patients in rural China. PLoS ONE. 2017;12(6):e0179425. https://doi.org/10.1371/journal.pone.0179425 .
doi: 10.1371/journal.pone.0179425
pubmed: 28628657
pmcid: 5476254
Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63(10):892–909. https://doi.org/10.4088/jcp.v63n1007 .
doi: 10.4088/jcp.v63n1007
pubmed: 12416599
MacEwan JP, Forma FM, Shafrin J, Hatch A, Lakdawalla DN, Lindenmayer JP. Patterns of adherence to oral atypical antipsychotics among patients diagnosed with schizophrenia. J Manag Care Spec Pharm. 2016;22(11):1349–61. https://doi.org/10.18553/jmcp.2016.22.11.1349 .
doi: 10.18553/jmcp.2016.22.11.1349
pubmed: 27783548
Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry. 2013;12(3):216–26. https://doi.org/10.1002/wps.20060 .
doi: 10.1002/wps.20060
pubmed: 24096780
pmcid: 3799245
Birnbaum M, Sharif Z. Medication adherence in schizophrenia: patient perspectives and the clinical utility of paliperidone ER. Patient Prefer Adherence. 2008;2:233–40. https://doi.org/10.2147/ppa.s3346 .
doi: 10.2147/ppa.s3346
pubmed: 19920968
pmcid: 2770423
Lauriello J, Lambert T, Andersen S, Lin D, Taylor CC, McDonnell D. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry. 2008;69(5):790–9. https://doi.org/10.4088/jcp.v69n0512 .
doi: 10.4088/jcp.v69n0512
pubmed: 18452346
Najarian D, Sanga P, Wang S, et al. A randomized, double-blind, multicenter, noninferiority study comparing paliperidone palmitate 6-month versus the 3-month long-acting injectable in patients with schizophrenia. Int J Neuropsychopharmacol. 2021;25(3):238–51. https://doi.org/10.1093/ijnp/pyab071 .
doi: 10.1093/ijnp/pyab071
pmcid: 8929757
Kane JM, Peters-Strickland T, Baker RA, et al. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2014;75(11):1254–60. https://doi.org/10.4088/JCP.14m09168 .
doi: 10.4088/JCP.14m09168
pubmed: 25188501
Nielsen RE, Hessellund KB, Valentin JB, Licht RW. Second-generation LAI are associated to favorable outcome in a cohort of incident patients diagnosed with schizophrenia. Schizophr Res. 2018;202:234–40. https://doi.org/10.1016/j.schres.2018.07.020 .
doi: 10.1016/j.schres.2018.07.020
pubmed: 30005935
Subotnik KL, Casaus LR, Ventura J, et al. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia. A randomized clinical trial. JAMA Psychiat. 2015;72(8):822–9. https://doi.org/10.1001/jamapsychiatry.2015.0270 .
doi: 10.1001/jamapsychiatry.2015.0270
Misawa F, Kishimoto T, Hagi K, Kane JM, Correll CU. Safety and tolerability of long-acting injectable versus oral antipsychotics: a meta-analysis of randomized controlled studies comparing the same antipsychotics. Schizophr Res. 2016;176(2–3):220–30. https://doi.org/10.1016/j.schres.2016.07.018 .
doi: 10.1016/j.schres.2016.07.018
pubmed: 27499361
Kishimoto T, Hagi K, Kurokawa S, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. Lancet Psychiatry. 2021;8(5):387–404. https://doi.org/10.1016/S2215-0366(21)00039-0 .
doi: 10.1016/S2215-0366(21)00039-0
pubmed: 33862018
Emsley R, Oosthuizen P, Koen L, Niehaus DJH, Medori R, Rabinowitz J. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Clin Ther. 2008;30(12):2378–86. https://doi.org/10.1016/j.clinthera.2008.12.020 .
doi: 10.1016/j.clinthera.2008.12.020
pubmed: 19167596
Ostuzzi G, Bertolini F, Del Giovane C, et al. Maintenance treatment with long-acting injectable antipsychotics for people with nonaffective psychoses: a network meta-analysis. Am J Psychiatry. 2021;178(5):424–36. https://doi.org/10.1176/appi.ajp.2020.20071120 .
doi: 10.1176/appi.ajp.2020.20071120
pubmed: 33596679
Kane JM, Schooler NR, Marcy P, et al. Effect of long-acting injectable antipsychotics vs usual care on time to first hospitalization in early-phase schizophrenia: a randomized clinical trial. JAMA Psychiat. 2020;77(12):1217–24. https://doi.org/10.1001/jamapsychiatry.2020.2076 .
doi: 10.1001/jamapsychiatry.2020.2076
Robinson DG, Subramaniam A, Fearis PJ, et al. Focused ethnographic examination of barriers to use of long-acting injectable antipsychotics. Psychiatr Serv. 2020;71(4):337–42. https://doi.org/10.1176/appi.ps.201900236 .
doi: 10.1176/appi.ps.201900236
pubmed: 31847736
Kane JM, Schooler NR, Marcy P, Achtyes ED, Correll CU, Robinson DG. Patients with early-phase schizophrenia will accept treatment with sustained-release medication (long-acting injectable antipsychotics): results from the recruitment phase of the PRELAPSE trial. J Clin Psychiatry. 2019;80(3):18m12546. https://doi.org/10.4088/JCP.18m12546 .
Iyer S, Banks N, Roy MA, et al. A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: part II-physician perspectives. Can J Psychiatry. 2013;58(5 Suppl 1):S23–S29. https://doi.org/10.1177/088740341305805s04 .
doi: 10.1177/088740341305805s04
Patel MX, Haddad PM, Chaudhry IB, McLoughlin S, Husain N, David AS. Psychiatrists’ use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years. J Psychopharmacol. 2010;24(10):1473–82. https://doi.org/10.1177/0269881109104882 .
doi: 10.1177/0269881109104882
pubmed: 19477883
Patel MX, Bent-Ennakhil N, Sapin C, et al. Attitudes of European physicians towards the use of long-acting injectable antipsychotics. BMC Psychiatry. 2020;20(1):123. https://doi.org/10.1186/s12888-020-02530-2 .
doi: 10.1186/s12888-020-02530-2
pubmed: 32169077
pmcid: 7071632
Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012;13(5):318–78. https://doi.org/10.3109/15622975.2012.696143 .
doi: 10.3109/15622975.2012.696143
pubmed: 22834451
Ascher-Svanum H, Zhu B, Faries DE, Furiak NM, Montgomery W. Medication adherence levels and differential use of mental-health services in the treatment of schizophrenia. BMC Res Notes. 2009;2:6. https://doi.org/10.1186/1756-0500-2-6 .
doi: 10.1186/1756-0500-2-6
pubmed: 19138402
pmcid: 2628922
Correll CU, Kim E, Sliwa JK, et al. Pharmacokinetic characteristics of long-acting injectable antipsychotics for schizophrenia: an overview. CNS Drugs. 2021;35(1):39–59. https://doi.org/10.1007/s40263-020-00779-5 .
doi: 10.1007/s40263-020-00779-5
pubmed: 33507525
pmcid: 7873121
Correll CU, Litman RE, Filts Y, et al. Efficacy and safety of once-monthly Risperidone ISM
doi: 10.1038/s41537-020-00127-y
pubmed: 33239746
pmcid: 7688968
Citrome L, Belcher E, Stacy S, Suett M, Mychaskiw M, Salinas GD. Management of schizophrenia with long-acting injectable antipsychotic medications: an assessment of the educational needs of clinicians [published correction appears in Schizophrenia]. Neuropsychiatr Dis Treat. 2022;18:111–23. https://doi.org/10.2147/NDT.S326299 .
doi: 10.2147/NDT.S326299
pubmed: 35115779
pmcid: 8801366
Blackwood C, Sanga P, Nuamah I, et al. Patients’ preference for long-acting injectable versus oral antipsychotics in schizophrenia: results from the patient-reported medication preference questionnaire. Patient Prefer Adherence. 2020;14:1093–102. https://doi.org/10.2147/PPA.S251812 .
doi: 10.2147/PPA.S251812
pubmed: 32753849
pmcid: 7342487
Bridges JFP, Slawik L, Schmeding A, Reimer J, Naber D, Kuhnigk O. A test of concordance between patient and psychiatrist valuations of multiple treatment goals for schizophrenia. Health Expect. 2013;16(2):164–76. https://doi.org/10.1111/j.1369-7625.2011.00704.x .
doi: 10.1111/j.1369-7625.2011.00704.x
pubmed: 21668795
McCrone P, Mosweu I, Yi D, Ruffell T, Dalton B, Wykes T. Patient preferences for antipsychotic drug side effects: a discrete choice experiment. Schizophrenia Bull Open. 2021;2(1):sgab046.
Achtyes E, Simmons A, Skabeev A, et al. Patient preferences concerning the efficacy and side-effect profile of schizophrenia medications: a survey of patients living with schizophrenia. BMC Psychiatry. 2018;18(1):292. https://doi.org/10.1186/s12888-018-1856-y .
doi: 10.1186/s12888-018-1856-y
pubmed: 30223804
pmcid: 6142379
Levitan B, Markowitz M, Mohamed AF, et al. Patients’ preferences related to benefits, risks, and formulations of schizophrenia treatment. Psychiatr Serv. 2015;66(7):719. https://doi.org/10.1176/appi.ps.201400188 .
doi: 10.1176/appi.ps.201400188
pubmed: 25772762
Gandell DL, Bienen EJ, Gudeman J. Mode of injection and treatment adherence: results of a survey characterizing the perspectives of health care providers and US women 18–45 years old. Patient Prefer Adherence. 2019;13:351–61. https://doi.org/10.2147/PPA.S187120 .
doi: 10.2147/PPA.S187120
pubmed: 30863023
pmcid: 6391128
El Abdellati K, De Picker L, Morrens M. Antipsychotic treatment failure: a systematic review on risk factors and interventions for treatment adherence in psychosis. Front Neurosci. 2020;14:531763. https://doi.org/10.3389/fnins.2020.531763 .
doi: 10.3389/fnins.2020.531763
pubmed: 33162877
pmcid: 7584050